Within the decade, the Stoughton-based company plans to bring non-opioid painkillers to market. And while CEO Joe Ciaffoni doesn’t think those new drugs will ever fully replace the company’s line of opioids, he and his team are planning a robust pipeline of new painkillers for the late 2020s.
Read More
